Gain Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
GANX$1.09+5.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| Operating expenses: · · · · | ||||||
| Research and development | | $(10,212,782) | | $(10,791,058) | ||
| General and administrative | | (8,497,920) | | (9,559,534) | ||
| Total operating expenses | | | (18,710,702) | | | (20,350,592) |
| | | | | | | |
| Loss from operations | | | (18,710,702) | | | (20,350,592) |
| | | | | | | |
| Other income (expense): | | | | | ||
| Interest income, net | | 244,394 | | 357,096 | ||
| Foreign exchange (loss) gain, net | | (833,673) | | 119,120 | ||
| Loss before income tax | | | (19,299,981) | | | (19,874,376) |
| | | | | | | |
| Income tax | | (861,118) | | (536,815) | ||
| | | | | | | |
| Net loss | | $(20,161,099) | | $(20,411,191) | ||
| | | | | | | |
| Net loss per shares: | | | | | ||
| Net loss per share attributable to common stockholders - basic and diluted | | $(0.61) | | $(0.89) | ||
| Weighted average common stock - basic and diluted | | 32,968,336 | | 22,881,415 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.